NKX2-5 and myocardial ischemia: Here we show that the most potent inhibitor (3i-1000) of GATA4–NKX2-5 interaction had beneficial effects on cardiac function and gene expression in several experimental models of myocardial ischemia and pressure overload, implicating that modulators of protein–protein interactions of key transcription factors may present a new class of pharmaceuticals for myocardial remodelling and repair.